X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (137) 137
female (114) 114
oncology (111) 111
index medicus (106) 106
breast cancer (97) 97
middle aged (81) 81
cancer (76) 76
adult (70) 70
breast neoplasms - pathology (65) 65
aged (64) 64
chemotherapy (63) 63
prognosis (55) 55
metastasis (53) 53
survival (51) 51
breast neoplasms - drug therapy (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (33) 33
care and treatment (31) 31
research (31) 31
metastases (29) 29
patients (29) 29
neoplastic cells, circulating - pathology (28) 28
therapy (28) 28
tumors (27) 27
breast neoplasms - mortality (26) 26
neoplasm staging (25) 25
circulating tumor cells (24) 24
disease-free survival (24) 24
hematology, oncology and palliative medicine (23) 23
medicine (23) 23
trastuzumab (23) 23
treatment outcome (23) 23
aged, 80 and over (22) 22
analysis (22) 22
bevacizumab (22) 22
receptor, erbb-2 - metabolism (22) 22
cancer therapies (21) 21
chemotherapy, adjuvant (20) 20
clinical trials (20) 20
mutation (20) 20
breast (19) 19
follow-up studies (19) 19
life sciences (19) 19
neoplasm metastasis (19) 19
biomarkers (18) 18
breast neoplasms - genetics (18) 18
peripheral-blood (18) 18
research article (18) 18
retrospective studies (18) 18
surgery (18) 18
antineoplastic agents - therapeutic use (17) 17
prospective studies (17) 17
male (16) 16
medical prognosis (16) 16
biopsy (15) 15
breast neoplasms - metabolism (15) 15
combined modality therapy (15) 15
erbb-2 protein (15) 15
kaplan-meier estimate (15) 15
metastatic breast cancer (15) 15
multidisciplinary sciences (15) 15
risk factors (15) 15
cancer patients (14) 14
multivariate analysis (14) 14
neoadjuvant chemotherapy (14) 14
oncology, experimental (14) 14
radiotherapy (14) 14
survival analysis (14) 14
adjuvant treatment (13) 13
antimitotic agents (13) 13
antineoplastic agents (13) 13
biomarkers, tumor - blood (13) 13
carcinoma (13) 13
circulating tumor dna (13) 13
science (13) 13
adjuvant chemotherapy (12) 12
breast neoplasms - surgery (12) 12
neoadjuvant therapy (12) 12
capecitabine (11) 11
cells (11) 11
deoxyribonucleic acid--dna (11) 11
expression (11) 11
fluorouracil - administration & dosage (11) 11
gene expression (11) 11
studies (11) 11
survival rate (11) 11
time factors (11) 11
trial (11) 11
young adult (11) 11
antibodies, monoclonal, humanized - administration & dosage (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
biomarker (10) 10
breast neoplasms - blood (10) 10
diagnosis (10) 10
dna (10) 10
follow-up (10) 10
mastectomy (10) 10
progression (10) 10
receptor, erbb-2 - genetics (10) 10
taxoids - administration & dosage (10) 10
breast neoplasms - therapy (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Chemistry, ISSN 0009-9147, 10/2019, p. clinchem.2019.304766
Journal Article
Breast, The, ISSN 0960-9776, 2015, Volume 24, pp. S29 - S30
Journal Article
Journal Article
Journal Article
Oncogene, ISSN 0950-9232, 09/2019
HER3, a member of the EGFR family of receptor tyrosine kinases coded by the ERBB3 gene, plays an important role in cancer, despite its lack of intrinsic kinase... 
Journal Article
Revue du Praticien, ISSN 0035-2640, 12/2013, Volume 63, Issue 10, pp. 1359 - 1361
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 02/2017, Volume 58, Issue 2, pp. 252 - 257
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 02/2017, Volume 58, Issue 2, p. 252
  Women who have breast cancer and are younger than 40 y have a poorer outcome than older women. A higher rate of undetected metastases at the time of... 
Nuclear medicine | Womens health | Breast cancer | Metastasis | Comparative analysis
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 02/2017, Volume 58, Issue 2, pp. 252 - 252
Women who have breast cancer and are younger than 40 y have a poorer outcome than older women. A higher rate of undetected metastases at the time of diagnosis... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 406 - 414
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer
Journal Article